Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
CRYSTALLINE FORM E OF TAFAMIDIS METHYLGLUCAMINE SALT, AND PREPARATION METHOD AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2017/190682
Kind Code:
A1
Abstract:
The present invention discloses a novel crystalline form E of a tafamidis methylglucamine salt, and a preparation method and application thereof. When compared to other known crystalline forms, the new crystalline form provided in the invention has the advantages of easy preparation, low technical requirements, and low hygroscopicity. The invention therefore provides a new and better option for preparing a pharmaceutical product comprising a tafamidis methylglucamine salt, and is very important for pharmaceutical product development.

Inventors:
CHEN MINHUA (CN)
ZHANG YANFENG (CN)
LI JIAOYANG (CN)
ZHANG XIAOYU (CN)
Application Number:
PCT/CN2017/083177
Publication Date:
November 09, 2017
Filing Date:
May 05, 2017
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
CRYSTAL PHARMATECH CO LTD (CN)
International Classes:
C07D263/57; A61K31/423; A61P25/00
Foreign References:
CN103781770A2014-05-07
CN100448852C2009-01-07
CN103781770B2016-04-13
Other References:
COELHO TERESA: "Tafamidis for transthyretin familial amyloid polyneuropathy", NEUROLOGY, vol. 79, no. 8, 21 August 2012 (2012-08-21), pages 785 - 792, XP055550363, ISSN: 0028-3878
NENCETTI SUSANNA: "Tafamidis (Vyndaqel): A Light for FAP Patients", CHEMMEDCHEM, vol. 8, no. 10, 2 September 2013 (2013-09-02), pages 1617 - 1619, XP055550365, ISSN: 1860-7179
Attorney, Agent or Firm:
LINDA LIU & PARTNERS (CN)
Download PDF: